Atossa Therapeutics ATOS shares are trading higher on Thursday after Ascendiant Capital initiated coverage on the stock with a Buy rating and a price target of $7 per share.
Atossa Therapeutics is a clinical-stage pharmaceutical company operating in the US. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions.
Atossa Therapeutics shares were up 9.78% at $2.47 at the time of publication on Thursday. The stock has a 52-week high of $5.08 and a 52-week low of 76 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
